GSK said its B7-H3-targeted ADC risvutatug rezetecan (ris-rez), partnered with Hansoh, met the Phase 3 primary endpoint of overall survival in advanced or relapsed small-cell lung cancer in China. The companies characterized the outcome as a milestone because they reported it as the first positive overall-survival Phase 3 data for a B7-H3 ADC in any tumor type. GSK is positioning the readout to support an approval push in China while continuing additional development, including a global Phase 3 program in extensive-stage small-cell lung cancer.